Geroprotective drug discovery with an AI-enabled assay for heat resistance
Hodder, T. J.; Nunes, A. D.; Martinez, B. A.; Opperman, K. J.; Robbins, P. D.; Myers, C. L.; Gill, M. S.
Show abstract
Drugs that slow the rate of organismal aging (geroprotectors) have the potential to improve human healthspan by preventing the development of multiple chronic diseases. The nematode C. elegans is a proven system for identifying anti-aging drugs, but methods for candidate nomination that scale to high throughput remain limited and have not been widely adopted. To accelerate the discovery process, we have developed an open-source AI-enabled screening platform that provides a rapid, automated, posture-based score of C. elegans survival. We used this workflow to screen a library of 2,782 FDA-approved drugs and identified 31 compounds that reproducibly increase heat stress resistance, a known predictor of longevity. Follow-up studies confirmed that many of these compounds confer lifespan extension in worms, and several compounds also have anti-senescent activity in human cells. This simplified and adaptable AI-enabled workflow therefore has the potential to accelerate the discovery of translatable drugs that slow aging.
Matching journals
The top 1 journal accounts for 50% of the predicted probability mass.
Similar papers in this journal
- scAgeClock: a single-cell transcriptome based human aging clock model using gated multi-head attention neural networks 95%
- Cyrene: A Novel Geroprotective Compound that Extends Lifespan and Healthspan in C. elegans and Drosophila 95%
- LinAge2: Providing actionable insights and benchmarking with epigenetic clocks 93%
Similar papers in this journal
Similar papers in this journal
- The natural flavonoid dihydromyricetin targets senescent cells via PRDX2 and alleviates age-related diseases 95%
- Using deep learning to predict age from liver and pancreas magnetic resonance images allows the identification of genetic and non-genetic factors associated with abdominal aging 94%
- Deciphering the Timing and Impact of Life-extending Interventions: Temporal Efficacy Profiler Distinguishes Early, Midlife, and Senescence Phase Efficacies 94%
Similar papers in this journal
- Evaluation of epigenetic and metabolomic biomarkers indicating biological age 93%
- Antecedent Metabolic Health and Metformin (ANTHEM) Aging study: Rationale and study design for a randomized controlled trial 92%
- Associations of Loneliness and Social Isolation with Healthspan and Lifespan in the US Health and Retirement Study 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.